Acer Therapeutics Inc (NASDAQ:ACER) – Research analysts at William Blair raised their Q2 2019 EPS estimates for Acer Therapeutics in a note issued to investors on Wednesday, May 15th. William Blair analyst T. Lugo now forecasts that the biopharmaceutical company will post earnings of ($0.83) per share for the quarter, up from their prior forecast of ($0.92). William Blair also issued estimates for Acer Therapeutics’ Q3 2019 earnings at ($0.69) EPS, Q4 2019 earnings at ($0.44) EPS, FY2019 earnings at ($2.66) EPS, Q1 2020 earnings at ($0.25) EPS, Q2 2020 earnings at ($0.10) EPS, Q3 2020 earnings at ($0.01) EPS, Q4 2020 earnings at $0.23 EPS and FY2020 earnings at ($0.17) EPS.
Acer Therapeutics (NASDAQ:ACER) last released its quarterly earnings results on Tuesday, May 14th. The biopharmaceutical company reported ($0.79) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.83) by $0.04.
ACER stock opened at $19.12 on Friday. The firm has a market capitalization of $214.26 million, a PE ratio of -7.68 and a beta of 2.46. Acer Therapeutics has a 1 year low of $16.02 and a 1 year high of $34.10.
A number of institutional investors have recently made changes to their positions in ACER. Bank of Montreal Can raised its holdings in Acer Therapeutics by 100.0% in the 4th quarter. Bank of Montreal Can now owns 3,210 shares of the biopharmaceutical company’s stock worth $64,000 after purchasing an additional 1,605 shares during the period. SG Americas Securities LLC bought a new position in Acer Therapeutics in the 1st quarter worth $101,000. Morgan Stanley raised its holdings in Acer Therapeutics by 114.0% in the 1st quarter. Morgan Stanley now owns 5,625 shares of the biopharmaceutical company’s stock worth $137,000 after purchasing an additional 2,996 shares during the period. Citigroup Inc. bought a new position in Acer Therapeutics in the 1st quarter worth $221,000. Finally, Laurion Capital Management LP bought a new position in Acer Therapeutics in the 1st quarter worth $253,000. 30.78% of the stock is currently owned by institutional investors.
Acer Therapeutics Company Profile
Acer Therapeutics Inc, a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes three clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; and ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders, maple syrup urine disease, and osanetant for the treatment of various neuroendocrine disorders.
Receive News & Ratings for Acer Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.